Abstract
HER2 overexpression has been associated with anti-estrogen resistance in human breast cancer, and it has been suggested that the combined treatment of an anti-HER2 antibody plus tamoxifen has enhanced anti-cancer efficacy in breast cancer. The detailed anti-proliferative interactions between trastuzumab and tamoxifen were analyzed with the isobologram and Chou and Talalay methods, which assess the presence of synergy, addition or antagonism. We used the breast cancer cell lines that are estrogen receptor (ER)-positive and HER2-positive. We also analyzed the molecular changes on the HER2 and (ER) signaling pathways that are induced by trastuzumab plus tamoxifen. In terms of cancer cell proliferation, the simultaneous combination of trastuzumab and tamoxifen on BT-474 cells was more growth inhibitory (44%) than the treatment with trastuzumab (24%) or tamoxifen (31%) alone. Isobologram analysis of simultaneous trastuzumab plus tamoxifen exposure showed, however, that there were antagonistic interactions at an effect level of 30% (IC30). Using Chou and Talalay analysis we also observed antagonistic interactions at lower levels of cell kill, although there were additive effects at highest levels of cell kill. Trastuzumab followed by tamoxifen showed antagonism at all effects levels. Tamoxifen followed by trastuzumab showed antagonism at lower levels of cell kill, and additivity at higher levels of cell kill. Similar interactions were observed using T47D cells. The molecular effects of the combined treatment with trastuzumab plus tamoxifen on the levels of HER2 and ER signaling showed that, with respect to HER2 protein levels, trastuzumab downregulated HER2 by 27%, tamoxifen upregulated HER2 by 40%, and the combination of trastuzumab plus tamoxifen did not induce changes in HER2 respect to control. With respect to HER2 mRNA, trastuzumab upregulated HER2 mRNA to 367%, tamoxifen to 166%, and the combination to 401%. With respect to HER2 phosphorylation, trastuzumab upregulated HER2 phosphorylation to 352%, tamoxifen to 202% and the combination to 633%. Epidermal growth factor receptor levels were not changed by trastuzumab or tamoxifen alone, and were upregulated to 138% by the combination. The protein levels and activity of extracellular recptor kinase were not modified by trastuzumab, tamoxifen or the combination. Finally, estrogen receptor protein and mRNA levels were downregulated to about 50% by trastuzumab, tamoxifen or the combination. Taken together, our results show that in ER-positive breast cancer cells overexpressing HER2, trastuzumab plus tamoxifen have antagonistic interactions when used in combination, and that this antagonism may be related with an increase in HER2 signaling pathways that occurs when tamoxifen is added to trastuzumab.
Similar content being viewed by others
References
Tzahar E, Yarden Y: The ErbB-2/Her2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377: M25–M37, 1998
Riese DJ, Stern DF: Specifity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41–48, 1998
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235: 177–182, 1987
Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveras B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356–2362, 2000
Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413–428, 1998
Yu D, Hung M-C: Overexpression of erbB-2 in cancer and erbB-2-targeting strategies. Oncogene 19: 6115–6121, 2000
Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM: Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treatment Res 61: 193–211, 1992
Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast Jr RC: Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 51: 5361–5369, 1991
Yarden Y: Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci USA 87: 2569–2573, 1990
Carter P, Presta L, Gorman CM, Ridway JBB, Henner D, Wong WLT, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289, 1992
Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T, Mitomi T: In vitro and in vivo anti-tumour effects of humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73: 1362–1365, 1996
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhanced the antitumor antivity of placlitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831, 1998
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–2251, 1999
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shack S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastasic breast cancer. J Clin Oncol 20: 719–726, 2002
Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonda A, Fleming T, Eiemann W, Wolter J, Norton L: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastasic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase II trial. Proc Am Assoc Clin Oncol 17: 98, 1998
Vollenwieder-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud I, Gomez F: The predictive value of estrogen and progesterone receptors concentrations on the clinical behavior of breast cancer in women. Clinical correlation of patients. Cancer 57: 1171–1180, 1986
Newby JC, Johnston SRD, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in breast cancer. Clin Cancer Res 3: 1643–1651, 1997
Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhaces tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887–5894, 2000
Janes PW, Daly RJ, deFazio A, Sutherland RL: Activa-tion of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9: 3601–3608, 1994
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491–1494, 1995
Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174–2183, 1996
Lupu R, Lippman ME: The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27: 83–93, 1993
Witters LM, Kumar R, Chinchilli VM, Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1–5, 1997
Menéndez JA, Barbacid MM, Montero S, Sevilla E, Escrich E, Solanas M, Cortés-Funes H, Colomer R: Effects of gamma-linolenic acid and oleic acid on paclit-axel cytotoxicity in human breast cancer cells. Eur J Cancer 37: 402–413, 2001
Menéndez JA, Ropero S, Barbacid MM, Montero S, Solanas M, Escrich E, Cortés-Funes H, Colomer R: Synergistic interaction between vinorelbine and gamma-linoleic acid in breast cancer cells. Breast Cancer Res Treat 72: 203–219, 2002
Berembaum MM: What is synergy? Pharmacol Rev 41: 93–141, 1989
Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: the combined Effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55, 1984
Larsen SS, Egeblad M, Jäättelä M, Lykkesfeldt AE: Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58: 41–56, 1999
Diel P, Smolnikar K, Michna H: The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58: 87–97, 1999
Saceda M, Grunt TW, Colomer R, Lippman ME, Lupu R, Martin MB: Regulation of estrogen receptor concentration and activity by an erb/Her ligand in breast carcinoma cell lines. Endocrinology 137: 4322–4330, 1996
Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Anaka K, Doihara H, Shimizu N, Sonoo H: Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 82: 46–51, 2000
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies adressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26(suppl 12): 60–70, 1999
Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318–321, 1992
Alimandi M, Romano M, Curia MC, Muraro R, Fedi P, Aaronson SA, DiFiore PP, Kraus MH: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transforma-tion and human mammary carcinomas. Oncogene 10: 1813–1821, 1995
Lewis GD, Figari I, Frendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255–263, 1993
Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ER? expression in breast cancer cells. Mol Endocrinol 15: 1344–1359, 2001
Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C: Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560–567, 1995
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ropero, S., Abel Menéndez, J., Vázquez-Martín, A. et al. Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma. Breast Cancer Res Treat 86, 125–137 (2004). https://doi.org/10.1023/B:BREA.0000032981.20384.c6
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000032981.20384.c6